Positive topline results for faricimab for neovascular age-related macular degeneration

Both the TENAYA and LUCERNE phase III studies (pooled n= 1,329) met their primary endpoint demonstrating that faricimab injections at fixed intervals of up to every 16 weeks achieved visual acuity outcomes that were non-inferior to aflibercept injections every eight weeks.

Source:

Biospace Inc.